Immune vulnerabilities of mutant KRAS in pancreatic cancer
Trends in Cancer · 2023-11 · 9 (11) · 928-936
DOI: 10.1016/j.trecan.2023.07.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-11. Verfasst von Noah C Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Lustgarten Foundation, Oregon Health and Science University.
Abstract (Originalsprache)
The 40-year desire to target the mutant Kirsten rat sarcoma (KRAS) gene (mKRAS) therapeutically is being realized with more and more broadly applicable and tumor-specific small-molecule inhibitors. Immunologically, mKRAS has equal desirability as a target. Tumor KRAS signaling plays a large role in shaping the immunosuppressive nature of the tumor microenvironment, especially in pancreatic cancer, leaving mKRAS inhibitors with potentially powerful immune modulatory capabilities that could be exploited in immunological-oncological combinations. mKRAS is itself an immunological antigen, a 'shared neoepitope' linked to the oncogenic process, validated biochemically and immunologically. Novel approaches in the clinic are taking advantage of the fact that mKRAS peptides are naturally processed and presented in tumors by the major histocompatibility complex (MHC).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: rhv@upenn.edu.
Förderung
- NCI NIH HHS
- Lustgarten Foundation
- Oregon Health and Science University
- Boston Children's Hospital
- University of Pennsylvania
- Parker Institute for Cancer Immunotherapy
- National Cancer Institute
Zitieren
APA
Cheng, N. C., & Vonderheide, R. H. (2023). Immune vulnerabilities of mutant KRAS in pancreatic cancer. Trends in Cancer, 9(11), 928-936. https://doi.org/10.1016/j.trecan.2023.07.004
Vancouver
Cheng NC, Vonderheide RH. Immune vulnerabilities of mutant KRAS in pancreatic cancer. Trends in Cancer. 2023;9(11):928-936. doi:10.1016/j.trecan.2023.07.004
BibTeX
@article{Cheng2023,
author = {Cheng, Noah C and Vonderheide, Robert H},
title = {Immune vulnerabilities of mutant KRAS in pancreatic cancer},
journal = {Trends in Cancer},
year = {2023},
volume = {9},
number = {11},
pages = {928--936},
doi = {10.1016/j.trecan.2023.07.004}
}
EUVIMED